Bicara Therapeutics Inc.
$23.47
▲
4.73%
2026-04-21 05:35:01
www.bicara.com
NGM: BCAX
Explore Bicara Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.57 B
Current Price
$23.47
52W High / Low
$24.25 / $7.8
Stock P/E
—
Book Value
$7.37
Dividend Yield
—
ROCE
-38.7%
ROE
-30.89%
Face Value
—
EPS
$-2.52
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
103
Beta
—
Debt / Equity
0.43
Current Ratio
14.58
Quick Ratio
14.58
Forward P/E
-6.95
Price / Sales
—
Enterprise Value
$969.58 M
EV / EBITDA
-6.24
EV / Revenue
—
Rating
Buy
Target Price
$30.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Adicet Bio, Inc. | $8.67 | — | $83.2 M | — | -71.49% | -67.55% | $17.44 / $6.01 | $14.82 |
| 2. | CNS Pharmaceuticals, Inc. | $2.69 | — | $2.06 M | — | -241.26% | -2.96% | $34.8 / $2.06 | $17.25 |
| 3. | Rhythm Pharmaceuticals, Inc. | $87.72 | — | $5.99 B | — | -51.31% | -90.45% | $122.2 / $55.31 | $2.07 |
| 4. | MAIA Biotechnology, Inc. | $1.41 | — | $81.91 M | — | -618.06% | -7.45% | $3.19 / $0.87 | $0.06 |
| 5. | Maze Therapeutics, Inc. | $26.84 | — | $1.4 B | — | -38.15% | -47.52% | $53.65 / $7.16 | $7.2 |
| 6. | Insmed Incorporated | $143.43 | — | $31.02 B | — | -55.4% | -2.49% | $212.75 / $63.81 | $3.45 |
| 7. | Tyra Biosciences, Inc. | $34.37 | — | $1.92 B | — | -50.19% | -39.83% | $40.65 / $7.8 | $4.83 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -41.12 M | -40.68 M | -32.02 M | -41.79 M | -26.64 M | — |
| Net Profit | -37.39 M | -36.33 M | -27.39 M | -36.85 M | -20.96 M | — |
| EPS in Rs | -0.57 | -0.55 | -0.42 | -0.56 | -0.32 | -1.6 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -155.6 M | -82.39 M | -39.89 M | -37.66 M |
| Net Profit | -137.95 M | -68 M | -51.98 M | -37.84 M |
| EPS in Rs | -2.11 | -1.04 | -0.79 | -0.58 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 430.99 M | 510 M | 233.98 M | 6.7 M |
| Total Liabilities | 29.54 M | 18.12 M | 382.75 M | 105.51 M |
| Equity | 401.45 M | 491.88 M | -148.77 M | -98.8 M |
| Current Assets | 422.05 M | 502.53 M | 231.07 M | 4.98 M |
| Current Liabilities | 28.95 M | 17.99 M | 15.09 M | 23.9 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -106.83 M | -74.75 M | -45.63 M | -32.08 M |
| Investing CF | -318.45 M | -0.01 M | -0.59 M | -0.19 M |
| Financing CF | 32.26 M | 334.03 M | 272.5 M | 31.7 M |
| Free CF | -107.11 M | -74.82 M | -46.21 M | -32.27 M |
| Capex | -0.28 M | -0.07 M | -0.59 M | -0.19 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -102.88% | -30.8% | -37.36% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.